Archive for Drugs and Treatments
HIFU has been a common primary prostate cancer treatment in Europe for quite a while. Currently, in the United States, there are a number of clinical trial sites evaluating HIFU as a primary treatment. Like all other primary treatments there is a significant failure rate causing men to move on to salvage therapy.
In Europe it isn’t uncommon for men who have failed HIFU treatment to undergo another course of HIFU as a salvage therapy.
At the Hôpital Universitaire Pellegrin, Bordeaux, researchers decided to evaluate an alternative, salvage radiotherapy (SRT) as a treatment following HIFU failure for localized prostate cancer. Read More→
New Drug for Advanced Prostate Cancer
Posted by: | Comments
New Drug for Advanced Prostate Cancer
Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial.
Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease progression. The use of ADT is strongly associated with very bothersome and some potentially fatal dangerous side effects. Side effects include metabolic syndrome, hot flashes, confusion, erectile dysfunction, cardiovascular disease, and type 2 diabetes and insulin resistance (Traish et al., 2009a,b,c). Clearly, nontoxic and economical therapeutic alternatives that prolong the interval between primary treatment failure and initiation of ADT would clearly be beneficial to both improving the quality of life and possibly extending survival. Read More→
Can Our Society Find Its Way To An Honest Dialogue About The Price Of A Human Life?
Posted by: | CommentsWhat is the real cost of approved treatments for advanced prostate cancer and how much we should spend? These questions are rippling through the prostate cancer community and the general population. Read More→
Docetaxel (Chemotherapy) Re-Treatment – Can It Work Again?
Posted by: | CommentsA group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy.
The researchers evaluated 45 men who had initially responded to docetaxel therapy and then had disease progression. The prospective multicenter study was conducted between November 2005 and January 2009. The men in the study were retreated with docetaxel (chemotherapy). Read More→
